Back

Identifying potential drug targets for non-alcoholic fatty liver disease: a drug target Mendelian randomization study

13 April 2024 (00:00 - 00:00)
Organised by: Logo
Congress Presentation Part of: Targets and markers of cardiometabolic disease Drugs, Drug Targets CBS PREMIUM ACCESS Frontiers in CardioVascular Biomedicine 2024 Council on Basic Cardiovascular Science

About the speaker

Photo
Miss Nikita Hukerikar

University College London, London (United Kingdom of Great Britain & Northern Ireland)

1 More presentation in this session

Presentation thumbnail
Circulating levels of amyloid-beta (1-40) peptide associate with cardiometabolic traits and risk for metabolic dysfunction-associated steatotic liver disease
Doctor K. Sopova (Mannheim, DE)
Abstract

Access the full session

Session thumbnail
Targets and markers of cardiometabolic disease

The Event

Event poster

Frontiers in CardioVascular Biomedicine 2024

13 April 2024 00:00 CET
You may be interested in
thumbnail
Congress Presentation
Identification of potential therapeutic targets for coronary artery disease based on protein array and Mendelian Randomization analysis
27 August 2021
thumbnail
Congress Presentation
Prevalence of non-alcoholic fatty liver disease measured by controlled attenuation parameter in patients with heart failure according to the left ventricular ejection fraction
29 June 2021
thumbnail
Congress Presentation
Autoantibodies directed against apolipoprotein-a-1 as a potential contributor to non-alcoholic fatty liver disease
27 August 2021
thumbnail
Congress Presentation
Steatotic liver disease and lipids in cardiometabolic syndrome
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources